AUA 2025 Annual Meeting
AUA 2025 Annual Meeting

The American Urological Association 2025 Annual Meeting is being held in Las Vegas, Nevada from April 26 to April 29.

Follow along with our exclusive updates from the meeting, featuring coverage of the most impactful sessions, groundbreaking research highlights, and exclusive video interviews with leading urologists.

Advertisement

Latest News

Comparative Performance of ctDNA, Imaging Studies in Monitoring Localized RCC Post-Surgery
Comparative Performance of ctDNA, Imaging Studies in Monitoring Localized RCC Post-Surgery
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Tumor Characteristics Associated with Preoperatively Detectable ctDNA in Patients With Renal Masses
Tumor Characteristics Associated with Preoperatively Detectable ctDNA in Patients With Renal Masses
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Perioperative Outcomes of Consolidative Surgery Following EV/Pembro for Advanced UC
Perioperative Outcomes of Consolidative Surgery Following EV/Pembro for Advanced UC
Alireza Ghoreifi, MDUrothelial Carcinoma | April 30, 2025
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
NMIBC: A Comprehensive Look at the Treatment, Therapeutic Landscape
NMIBC: A Comprehensive Look at the Treatment, Therapeutic Landscape
Patrick Gomella, MDNon-Muscle Invasive Urothelial Carcinoma | April 30, 2025
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
AUA Guidelines: Salvage Therapy for Prostate Cancer
AUA Guidelines: Salvage Therapy for Prostate Cancer
Edwin Posadas, MDLocalized | April 29, 2025
Drs. Posadas and Ambinder reflect on the first AUA guideline update for salvage therapy in prostate cancer in over a decade.
Niraparib for DDR-Deficient Localized Prostate Cancer: Results From a Phase 2 Study
Niraparib for DDR-Deficient Localized Prostate Cancer: Results From a Phase 2 Study
Marc Dall'Era, MDLocalized | April 29, 2025
Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa.
Boosting HRQoL After Disease Recurrence Post-Radical Cystectomy
Boosting HRQoL After Disease Recurrence Post-Radical Cystectomy
Samuel Gold, MDUrothelial Carcinoma | April 28, 2025
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
CISTO: Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade NMIBC
CISTO: Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade NMIBC
John Gore, MD, MSUrothelial Carcinoma | April 28, 2025
Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.
TAR-200 for BCG–Unresponsive High-Risk NMIBC CIS: 1-Year Durability, PROs
TAR-200 for BCG–Unresponsive High-Risk NMIBC CIS: 1-Year Durability, PROs
Joseph Jacob, MD, MCRUrothelial Carcinoma | April 28, 2025
Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC.
ADVANCED-2: Intravesical TARA-002 in Patients with High-Grade NMIBC
ADVANCED-2: Intravesical TARA-002 in Patients with High-Grade NMIBC
Gautam T. Jayram, MDUrothelial Carcinoma | April 29, 2025
Dr. Jayram highlights the updates in the ADVANCED-2 study: TARA-002 for patients with high-grade NMIBC.
Early Discontinuation of Upfront ARSIs Without Disease Progression in Patients With mCSPC
Early Discontinuation of Upfront ARSIs Without Disease Progression in Patients With mCSPC
Zachary BessettemCSPC | April 27, 2025
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Testosterone Recovery Observed in Majority of Patients Following Treatment Suspension in EMBARK Trial
Testosterone Recovery Observed in Majority of Patients Following Treatment Suspension in EMBARK Trial
Brandon TwyfordProstate Cancer | April 27, 2025
Most patients in EMBARK recovered testosterone after treatment break, regardless of therapy or age.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Brad McGregor, MDMuscle Invasive Urothelial Carcinoma | August 14, 2024
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Christopher Kane, MDProstate Cancer | March 24, 2025
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and lead in urology.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
RLT
RLT
mHSPC/mCSPC
mHSPC/mCSPC
Renal Cell Carcinoma
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Urothelial Carcinoma
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma Diagnostics
Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
Dr. Mark Tyson from Mayo Clinic joins the podcast to discuss the high CR rate seen in cohort C of the BOND-003 trial.
# Posted on April 27, 2025
# Uromigos-Bladder Cancer
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in High-Risk NMIBC
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in High-Risk NMIBC
Dr. Neal Shore joins the show to discuss exciting data from the CREST trial.
# Posted on April 27, 2025
# Uromigos-Bladder Cancer
Episode 407: Drug Development in China: Part 2 of 2
Episode 407: Drug Development in China: Part 2 of 2
Part 2 dives deeper into the explosion of ADC clinical drug development in China.
# Posted on April 21, 2025

Conference Coverage

Live meeting highlights

Comparative Performance of ctDNA, Imaging Studies in Monitoring Localized RCC Post-Surgery
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
View More
Tumor Characteristics Associated with Preoperatively Detectable ctDNA in Patients With Renal Masses
Reuben Ben-David, MDRenal Cell Carcinoma Diagnostics | April 30, 2025
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
View More
Perioperative Outcomes of Consolidative Surgery Following EV/Pembro for Advanced UC
Alireza Ghoreifi, MDUrothelial Carcinoma | April 30, 2025
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
View More
NMIBC: A Comprehensive Look at the Treatment, Therapeutic Landscape
Patrick Gomella, MDNon-Muscle Invasive Urothelial Carcinoma | April 30, 2025
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |